Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer

Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk population. Patients with TNBC or deleterious BRCA mutation (TNBC/B...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Breast Cancer
Main Authors: Kalra, Maitri, Tong, Yan, Jones, David R., Walsh, Tom, Danso, Michael A., Ma, Cynthia X., Silverman, Paula, King, Mary-Claire, Badve, Sunil S., Perkins, Susan M., Miller, Kathy D.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7985189/
https://ncbi.nlm.nih.gov/pubmed/33753748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-021-00240-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados